CANCER.
Information on current developments in both regular and alternative or complementary treatments for cancer types and resources at all stages. We have basically all articles and information put in alphabetical order, scroll in left column in alphabetical list.
Experiences of cancer patients with complementary approaches can be found by experience stories and there are also some videos of experiences of cancer patients to see. To click on video button top left . Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
Erbitux - Cetuximab shows no positive effect in addition to chemotherapy in colorectal cancer (FOLFOX regimen). Phase III trial is therefore broken. Erbitux does work in cancer patients with wild type KRAS, even without chemo. Article updated October 21, 2010
October 21, 2010: For more articles and recent developments on Erbitux - Cetuximab in damrkanker and lung cancer , click here .
December 17, 2009: Source: NCI - http://www.cancer.gov/newscenter/pressreleases/CetuximabClosure
Erbitux - Cetuximab does not help when added to FOLFOX chemotherapy as postoperative treatment for stage III colon cancer. Therefore, the ethics commission decided a phase III study prematurely abort. .
The analysis shows between the - N0147 - randomized study that patients with stage III colon cancer after surgery, either FOLFOX alone or FOLFOX chemotherapy and Erbitux were there no difference in outcome was noted. Even in cancer patients with the KRAS gene. Once information about the importance of the KRAS gene for Erbitux was discovered, all patients in the studei their tumors tested for KRAS mutations and only those with a normal or wild-type KRAS were included in the DMC-analysis.
According to the NCI news release, there was a preliminary finding that the addition of Erbitux could be harmful, particularly in patients older than 70.
The study was led by the NCCT group and sponsored by the NCI.
NCCTG N) -147 was officially titled: A randomized phase III trial of Oxaliplatin Plus 5-Fluorouracil/Leucovorin with or without Cetuximab after curative resection for patients with Stage III Colon Cancer
Currently, the use of Erbitux for colorectal cancers restricted to patients with metastatic disease who do not have mutations in the KRAS gene.
